Comorbidities, biomarkers and severe COVID-19

**Inclusion criteria**

- **18+**
- Age >18 years-old
- Symptomatic hospitalized patients
- Confirmed SARS-CoV-2 infection
- Informed consent

N= 336 patients

- Non severe 253 (75%)
- Severe 83 (25%)

**Associated with severity**

**Characteristics and comorbidities**

- Age
- Male sex
- Obesity
- Obstructive sleep apnea

**Biomarkers**

- LDH >600 U/L
- Serum ferritin >500 mcg/L
- Interleukin-6 >40 pg/mL
Prevalence of cardiac amyloidosis in heart failure (PREVAMIC)

**Inclusion criteria**
- Age ≥ 65 years-old
- HF diagnosis (ESC 2016 Guidelines)
- Internal Medicine: inpatients or outpatients
- LVEF: any value
- LVH: septum or posterior wall > 12 mm
- NYHA class II-IV
- Diuretic treatment in the last 6 months
- Elevated natriuretic peptides
- Informed consent

**Inclusion visit**
- HF-related variables
- Comorbidities
- Functional/cognitive status
- Amyloidosis specific data
- Basic laboratory tests
- Complementary procedures

**Cardiac scintigraphy:** 99mTc-OPD/PYP/HMDP
**Serum FLCs and serum and urine IFE**

**One-year follow-up visit**
- Hospital admissions
- ED visits
- Mortality

**ATTR:** transthyretin amyloidosis; **ED:** Emergency Departments; **ESC:** European Society of Cardiology; **FLCs:** free light chains; **HF:** heart failure; **IFE:** immunofixation electrophoresis; **LVEF:** left ventricular ejection fraction; **LVH:** left ventricular hypertrophy; **NYHA:** New York Heart Association; **TTR:** transthyretin.